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Background: The combination platinum, 5-fluorouracil (5-FU) and cetuximab is the standard first-line regimen of
recurrent and/or metastatic head and neck squamous cell carcinoma (HNSCC). Due to the toxicity of this treatment,
alternative therapies are often offered to patients. The aim of this study was to evaluate the overall survival obtained
with a first line chemotherapy adapted to patients functional status and the administration of all active drugs within
successive lines of chemotherapy.
Methods: This series included a total of 194 patients with recurrent and/or metastatic HNSCC treated from 2006 to
2011 in a single institution where the administration of successive lines of chemotherapies has been the standard
clinical approach. Treatment was administered according to clinical practice guidelines.
Results: Most patients received at least two treatment lines. Only 11 patients (6%) were treated with a combination of
cisplatin, 5-FU and cetuximab in front line, but most patients received at least one platinum-based regimen (n = 154
patients, 78%); 162 (82%) received taxanes, 36 (18%) received 5-FU, 27 (14%) received capecitabine, 67 (34%) received
methotrexate and 134 (68%) received cetuximab. The median overall survival was 9.8 months (95% CI: 8.1-11.4 months)
and reached 13.1 months among the subgroup of 131 patients eligible for inclusion in a clinical trial.
Conclusion: The survival outcomes of patients treated in the first-line setting with chemotherapy regimens adapted to
their functional status, followed by several subsequent regimens were comparable with published outcomes of patients
treated by platinum, 5-FU and cetuximab.
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Despite progress in the primary treatment of head and
neck squamous cell carcinoma (HNSCC) by combining
chemotherapy with surgery, radiation therapy and sup-
portive care, recurrence rates range from 30 to 50%. For
the treatment of recurrent and/or metastatic HNSCC,
platinum-based combination chemotherapy has been the
standard first-line treatment, providing a median overall
survival (OS) of six to nine months [1-5]. However, since* Correspondence: julien.peron@ymail.com
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reproduction in any medium, provided the orthe combination of cisplatin, 5-fluorouracil (5-FU) and
cetuximab was shown to be superior to that of cisplatin,
5-FU and placebo in the EXTREME phase III trial [5],
it became the new standard for first-line treatment of
recurrent and/or metastatic patients. Response rates
significantly increased from 20 to 36%, together with
progression-free survival (PFS) (from 3.3 to 5.6 months)
and OS (from 7.4 to 10.1 months; HR = 0.80; 95% CI:
0.64-0.99; p = 0.04). Only 6% of patients treated with
chemotherapy alone received cetuximab after the study
was completed. Thus, cetuximab has become a key
drug for the treatment of recurrent and/or metastatic
HNSCC; however, its most effective place in the treat-
ment strategy remains to be determined.td. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited.
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scale ≥ 70%) and with adequate organ function were
included in the EXTREME trial. Nevertheless there
were more cases of febrile neutropenia (9 patients vs.
1, p = 0.02), cutaneous toxicity (9% of grade 3–4) and
allergic reaction in the group of patients treated with
cetuximab. Given the efficacy shown by cetuximab
administered as a single agent [6] or in combination with
less toxic chemotherapeutic agents, such as taxanes [7,8],
first-line treatment with the highly toxic combination of
cetuximab and platinum-based chemotherapy might be
avoided without loss of efficacy. After failure of first-line
platinum-based chemotherapy, further chemotherapy
regimens are now available. Indeed, taxanes alone [9,10]
or taxanes in combination with cetuximab [7,8], cape-
citabine [11,12] or methotrexate [1] are available as
subsequent treatment lines.
Given the low tolerability of the combination cisplatin-
5FU plus cetuximab, most patients in our institution did
not receive cetuximab as first-line treatment, but later,
during follow-up. Therefore, we retrospectively analyzed
the outcomes of patients treated in a single institution,
where the administration of successive lines of chemo-
therapies has been the standard clinical approach.Paent eligible for cisplan base
1. CDDP-5FU
2. Aer authorizaon of cetuximab: CDDP-5FU-Cetuximab
3. Before a putave salvage surgery: CDDP- 5FU-Docetaxel
4. For the TPEX trial: CDDP-Docetaxel-Cetuximab

















Figure 1 Chemotherapy guidelines for patients with recurrent and/orMethods
Data retrieval and file selection
We retrospectively reviewed the data of all patients with
histologically confirmed recurrent and/or metastatic
HNSCC and treated by chemotherapy at a single insti-
tution between March 2006 and August 2011. Previous
chemotherapy could have been administered for the
treatment of the primary tumor (induction chemother-
apy or in combination with radiation therapy). Written
consent was obtained from each patient according to
the institutional practice and french regulation. This
study was approved by the ethics committee of the Centre
Léon Bérard cancer center. Patient data were collected in
accordance with CNIL rules (the French authority for pro-
tection of patient data) and kept anonymous.
Treatment
Treatment was administered according to clinical prac-
tice guidelines (Figure 1). The choice of first-line ther-
apy depended on the date of treatment onset, the
patients’ condition and the efficacy or residual toxicity
of previous platinum-based chemotherapy when used
in treatment for localized disease. Recent local clinical
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than 6 months after the end of the multimodal treat-
ment including platinum for locoregional disease) with
cisplatin in combination with taxanes alone, 5-FU
alone, or 5-FU and cetuximab in the first-line setting.
Common cisplatin ineligibility criteria were renal dys-
function (creatinine clearance of < 50 to 60 mL/min),
poor performance status, advanced age (>70 to 75 years),
and comorbidities (eg, severe neuropathy, congestive
heart failure, hearing loss). Cisplatin-ineligible patients
received a 3-weekly AUC5 carboplatin-based chemo-
therapy (Figure 1). Patients with highly impaired per-
formans status (Karnofsky score below 50) or with
highly impaired nutritional status could be ineligible
to carboplatin. Carboplatin-ineligible patients and pa-
tients treated in the second-line setting who developed
a resistance to platinum (progressive disease less than
6 months after the beginning of platinum) received a
combination of paclitaxel ± cetuximab. If the first-line
efficacy of the platinum-based chemotherapy was good, a
combination of cisplatin and cetuximab could be proposed
after progression. Subsequent lines consisted of inclusion
in a clinical trial, methotrexate, or capecitabine, depending
on previously given therapies and eligibility in a clinical
trial. Each chemotherapy line was continued until disease
clinical or radiological progression or significant toxicity.
Chemotherapy regimens commonly used in our institu-
tion are described in the Table 1.
Analysis
OS was defined as the time elapsed from the first dose
of chemotherapy administered for the recurrent and/or
metastatic disease. If death did not occur before the
cut-off date, the patient was censored at the date of last
valid assessment. The primary endpoint of the studyTable 1 Description of the common chemotherapy regimens
Platinum based regimens (name and dose)
Cisplatin (100 mg/m2/3 weeks) + 5-FU
(1000 mg/m2/d, 5 days/3 weeks)
Cisplatin (75 mg/m2/3 weeks) + Docetaxel (75 mg/m2/3 weeks)
Cisplatin (75 mg/m2/3 weeks) + Docetaxel
(75 mg/m2/3 weeks) + Cetuximab (400 mg/m2 then 250 mg/m2/week)
Cisplatin (75 mg/m2/3 weeks) + Docetaxel
(75 mg/m2/3 weeks) + 5-FU (750 mg/m2/d, 5 days/3 weeks)
Cisplatin (100 mg/m2/3 weeks) + 5-FU (1000 mg/m2/d, 4 days/3 weeks)
+ Cetuximab (400 mg/m2 then 250 mg/m2/week)
Carboplatin (AUC5/3 weeks) + 5-FU (1000 mg/m2/d, 4 days/3 weeks)
+ Cetuximab (400 mg/m2 then 250 mg/m2/week)
Carboplatin (AUC5/3 weeks) + Paclitaxel (80 mg/m2/week)
Carboplatin (AUC5/3 weeks)
5-FU = 5-Fluorouracil.
AUC = Area Under the Curve.was the estimation of the median OS. Inclusion of at
least 150 patients was hoped to provide a sufficient pre-
cision in the estimation of the median OS (less than
6 months confidence interval range). Survival distribu-
tions were estimated by the Kaplan-Meier method. To
evaluate the impact on OS of factors known to be rele-
vant in recurrent and/or metastatic HNSCC prognosis,
potential prognostic factors were included in univariate
and multivariate Cox proportional hazard regression
models.
Patients were considered ineligible for inclusion in a
clinical trial at the time of the first line of chemotherapy
for recurrent or metastatic disease if they had a perfor-
mans status ≥ 2, life-threatening severe comorbidity,
concomitant malignancy or disease progression within
six months of curative-intent treatment for localized dis-
ease. Analyses were conducted among the entire study
population and then restricted to patients virtually de-
fined as eligible for inclusion in a clinical trial. All ana-
lyses were performed with SPSS v19.0 (SPSS Inc.,
Chicago, Illinois) and R (http://www.R-project.org/).
Results
Patient characteristics
Between March 2006 and August 2011, a total of 198
patients with histologically confirmed HNSCC received
chemotherapy at the Centre Léon Bérard (Lyon, France)
for a recurrent and/or metastatic disease. The character-
istics of the study population are summarized in Table 2.
The patients were mostly men (n = 171; 86%) with a me-
dian age of 61 years (ranging from 29 to 87 years) at the
time of initiation of palliative chemotherapy.
The three most common sites of primary tumor were
the oral cavity (n = 54; 27%), the oropharynx (n = 55;
28%) and the hypopharynx (n = 47; 24%). The tumorsused in the series
Platinum free regimens (name and dose)
Paclitaxel (60 to 80 mg/m2/week) + Cetuximab
(400 mg/m2 then 250 mg/m2/week)
Paclitaxel (80 mg/m2/week)
Methotrexate (40 mg/m2/week)
Capecitabine (1,000 mg/m2 BID for 14 days/21 days)
Table 2 Baseline Demography of the Patient Population
Median age, years [range] 61 [29–87]



















Neoadjuvant platinum based chemotherapy 52 (26)
With Fluorouracil 43 (22)




With platinum 74 (37)
With cetuximab 20 (10)
With taxanes 1 (1)
Pattern of disease
Primary metastatic 13 (7)
Primary locally advanced (palliative treatment) 8 (4)
Relapse 177 (89)
Local only 126 (63)
Metastatic +/− local 51 (26)
Eligibility for inclusion in a clinical trial
Yes 131 (66)
No 67 (34)
PS ≥ 2 53 (27)
Relapse after initial therapy≤ 6 months 27 (14)
Other concomitant malignancy 3 (2)
Major comorbidity 3 (2)
PS at onset of palliative chemotherapy
0 28 (14)
1 117 (59)
≥ 2 53 (27)
*Four nasopharynx, 12 sinus tumor, 5 primitive adenopathies.
PS = Perormans Status.
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patients had metastases, 122 (62%) patients had stage IVa
or IVb tumors, and 23 (12%) patients had stage III tumors.
Among patients treated in relapse (n = 177; 89%), ini-
tial treatment consisted of neoadjuvant platinum-based
chemotherapy for 52 patients (26% of the whole cohort);
142 (72%) patients underwent surgery, and 168 (85%)
received radiation therapy alone (n = 73; 37%) or in
combination with chemotherapy (n = 75; 38%) or cetux-
imab (n = 20; 10%). Overall, 67 patients (34%) were in-
eligible for inclusion in a clinical trial, mainly because of
a performance status ≥ 2 (n = 53; 27%), severe comor-
bidity or concomitant malignancy (n = 6; 3%) or disease
progression within six months of curative-intent treat-
ment for localized disease (n = 27; 14%).
Mode of chemotherapy delivery
Data about chemotherapy delivery are summarized in
Table 3. The most frequent first-line regimens chosen by
physicians were those combining taxanes and carbopla-
tin (n = 69; 35%) or cisplatin (n = 46; 23%), and mainly
the combination of carboplatin and paclitaxel. Thirteen
patients received the cisplatin, docetaxel and cetuximab
combination evaluated in the TPEx trial [13]. Platinum
without taxane combinations were administrated to only
28 patients (14%), including 11 patients (6%) treated
with a combination of cisplatin, 5-FU and cetuximab, at
the same schedule as in the EXTREME trial. Overall,
154 patients (78%) received at least one platinum-based
regimen for the treatment of the recurrent and/or
metastatic disease; 162 (82%) received taxanes, 36
(18%) received 5-FU, 27 (14%) received capecitabine,
67 (34%) received methotrexate, 134 (68%) received
cetuximab, and 27 (14%) patients were included in at
least one clinical trial for a novel agent (Table 3). On
average, the patients eligible for inclusion in a clinical
trial at the onset of palliative chemotherapy received a
slightly higher number of chemotherapy lines and were
exposed for a longer time to the different chemothera-
peutic drugs (Table 3).
Efficacy
After a median follow-up of 33.4 months, a total of 156
patients (79%) had died. The median OS was 9.8 months
(95% CI: 8.1-11.4 months) (Table 4). The outcomes of
patients treated with first-line platinum-based chemo-
therapy were consistently acceptable. The median OS of
patients treated with a combination of cisplatin and
taxanes, carboplatin and taxanes, or a platinum-based
combination without taxane were 14.2, 10.5 and 11.2 months,
respectively (Table 5). Among the subgroup of patients
eligible for inclusion in a clinical trial (n = 131; 66%), the
median OS was 13.1 months (95% CI: 11.2-17.8 months)
(Figure 2, Table 4), reaching up to 16.6 months (95% CI:
Table 3 Treatment Settings
Number of chemotherapy lines in
recurrent or metastatic setting
Among the whole
cohort (N = 198)
Among patients eligible for
inclusion in a clinical trial (N = 131)
No. of patients (%) No. of patients (%)
1 74 (37) 33 (25)
2 47 (24) 37 (28)
3 44 (22) 33 (25)
4 23 (12) 19 (15)
5 or more 10 (5) 9 (7)
Chemotherapy drug used
Taxanes 177 (89) 122 (93)
Including recurrent or metastatic setting 162 (82) 116 (89)
CDDP or Carboplatin 185 (93) 127 (97)
Including recurrent or metastatic setting 154 (78) 114 (87)
5FU 78 (39) 62 (47)
Including recurrent or metastatic setting 36 (18) 32 (24)
Cetuximab 144 (73) 103 (79)
Including recurrent or metastatic setting 134 (68) 100 (76)
Capecitabine in recurrent or metastatic setting 27 (14) 23 (18)
Methotrexate in recurrent or metastatic setting 67 (34) 39 (30)
Novel agent tested in a clinical trial in recurrent or metastatic setting 27 (14) 27 (21)
Drug combination used in first line of the recurrent/metastatic disease
Platinum based combination 143 (72) 103 (79)
Cisplatin + taxanes 46 (23) 40 (31)
Carboplatin + taxanes 69 (35) 40 (31)
Platinum without taxanes 28 (14) 23 (18)
Including CDDP 5FU and cetuximab combination 11 (6) 10 (8)
Taxanes and cetuximab combination 14 (7) 8 (6)
Monotherapy 34 (17) 13 (10)
Clinical trials testing not approved regimens 7 (4) 7 (5)
CDDP = Cisplatin ; 5FU = 5-Fluorouracil.
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line cisplatin. A performans status ≥ 2, an age ≥ 60 years
and a prior treatment with anti- epidermal growth-factor
receptor were predictors of a poor OS in univariate ana-
lysis. Only a performans status ≥ 2 was independently
associated with OS in multivariate analysis.
Safety
Five patients (3%) died as a result of adverse events at least
possibly related to chemotherapy. Three of this patientTable 4 Survival of patients
Median overall survival
Time in months (95% CI)
Among the whole cohort (N = 198) 9.8 (8.1-11.4)
Among patients eligible for inclusion
in a clinical trial (N = 131)
13.1 (11.2-17.8)died of febrile neutropenia after first line carboplatin and
paclitaxel combination. All had severe comborbidities
or impaired functional statues at the onset of chemother-
apy (liver transplantation; anorexia leading an important
weight loss; age > 80 years and impaired functional status).
One patient died of an anaphylactic shock after the first
course of paclitaxel and cetuximab. One patient died of an
aspiration pneumonia on feeding tube a few days after the
onset of cisplatin, 5-FU and docetaxel combination. The
relation between the chemotherapy and the pneumonia is
uncertain.
Discussion
The results of this study challenge the use of the platinum,
5-FU and cetuximab combination for the first-line treat-
ment of recurrent and/or metastatic HNSCC. Indeed, we
showed here that the sequential use of all efficient chemo-
therapy regimens led to an OS of 9.8 months among a





Cisplatin + taxanes (N = 46) 14.2 (10.8-19.6)
Carboplatin + taxanes (N = 69) 10.5 (7.6-13.1)
Platinum without taxanes (N = 28) 11.2 (8.6-25.3)
Other chemotherapy (N = 48) 5.6 (4.3-8.1)
Clinical trials testing not approved
regimens (N = 7)
5.7 (1.7 – NR)
NR = Non Reached.
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reached 13.1 months among patients without classical
major exclusion criteria for clinical trials.
Today, the first-line standard treatment for recurrent
and/or metastatic HNSCC is the combination of platinum,
5-FU and cetuximab, which is continued as maintenance
therapy since the EXTREME trial demonstrated an overall
response rate of 36%, a median PFS of 5.6 months, and a
median OS of 10.1 months vs. 20%, 3.3 and 7.4 months
without cetuximab, respectively. However, there were more
severe adverse events in the arm of patients treated with
cetuximab. The EXTREME trial only included patients
in good general condition (with a Karnofsky > =70%),
with adequate organ function, and with a relapse-free
interval of at least six months since the last chemother-
apy for the treatment of the local disease [5]. Because of
the high toxicity, many patients with impaired nutri-
tional or functional status are not eligible for this regi-
men, and other therapeutic strategies should be offered












Overall Survival among the whole cohort
Median Survival: 9.8 months
95% confidence interval: 8.1-11.4
Number of alive patients 198 112470
A
Figure 2 Kaplan-Meier estimates of overall survival among the whole
trial (B).In our series, platinum-based combination was the
favored first line when patients were fit enough, to
avoid subsequent platinum-ineligibility related to dis-
ease progression. Patient ineligible for cisplatin and for
the platinum, 5-FU and cetuximab combination were
treated with a carboplatin-based front line therapy. The
combination of carboplatin and weekly paclitaxel showed
response rates of 48 to 53% and median survival rates of 8
to 12.8 months in Phase II trials [14,15]. In addition,
the tolerability was better than with a traditional three-
weekly administration [14,16]. This combination could
then be proposed to patients with an impaired general
condition (with a performance status of 2 or >2). For
these reasons, carboplatin and weekly paclitaxel was
the standard carboplatin-based regimen in this series.
For patients ineligible or resistant to a platinum ther-
apy, less toxic first line regimens have been offered to
patients. The efficacy of taxanes as monotherapy [9,10]
or in combination with cetuximab [7,8,17] after failure
of platinum-based chemotherapy has been shown in
several studies, with a response rate of 30% as mono-
therapy and a response rate of 38 to 54% for the com-
bination. The tolerability profiles were good for both
monotherapy and the combination. Thus, platinum,
taxanes and cetuximab appear to be drugs of choice for
the treatment of recurrent and/or metastatic HNSCC,
and could be used either in combination or as succes-
sive therapies.
Since the approval of cetuximab for the treatment of
recurrent and/or metastatic HNSCC, the comparison
between several lines of single agent vs. combination
chemotherapy regimens has never been performed in a
clinical trial. In 1992, in a trial comparing cisplatin and














Overall Survival among patients elligible for
inclusion in a clinical trial
Median Survival: 13.1 months
95% confidence interval: 11.2 - 17.8
8 131 102263 8
B
cohort (A) and among patients eligible for inclusion in a clinical
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improve. In other cancer subtype, it appears more im-
portant for patients to receive all the active agents at
some point during the course of treatment rather than the
order or combination in which the drugs are received
[18-20]. Considering the high rate of comorbidities, im-
paired nutritional status, and impaired functional status
of patients with recurrent and/or metastatic HNSCC,
they should be treated with less toxic strategies. Thus,
successive chemotherapy lines could be an effective
treatment option. The higher response rate observed
with combination strategy [5] has been shown to im-
prove the functional status of patients [21]. Moreover
some patients in this series never received cetuximab. It
appears that some patients would never receive any sec-
ond line treatment given a rapid disease progression
after failure of the first line regimen. The successive
chemotherapy lines strategy might then be more suited
for patients with low cancer-related symptoms, and
with low tumor burden.
In this series, only 6% of the patients were treated in
first line with the combination of platinum, 5-FU and
cetuximab. First line therapy was adapted to patients’
general status and comorbidities. A major objective
pursued by treating oncologists was to give all the
active agents to a maximum of patients, explaining
the high rate of patients receiving platinum, taxanes,
cetuximab, methotrexate and 5-FU at least once. The
estimation of patient’s outcomes in this series might
be biased, given the retrospective nature of the study,
the high heterogeneity of the patients and of the
treatments.
Supportive care performed during and after the chemo-
therapy could have increased patients outcomes, as early
integration of supportive care has been associated with
survival benefit in another cancer setting (lung cancer)
[22], but teoretically could be transposed to head and neck
cancer and deserve further studies. However because all
consecutive patients treated in our institution have been
included in this series, it might be a relevant estimation of
“real life” patient outcomes. Even if a formal comparison is
not possible between our retrospective study and the re-
sults of clinical trials, the OS in our study was higher than
those obtained with a combination of platinum, 5-FU and
cetuximab in first line [23]. The high number of successive
chemotherapy line (39% of patients received 3 lines or
more) might explain patients good outcomes. Because of
the heterogeneity of the treatment described in this study,
and because of the limitations of a retrospective study, we
did not assess the adverse events rates of the successive
chemotherapy lines strategy. However, the tolerability of
multiple successive chemotherapy regimens should com-
pare favorably with multiple-drugs combinations [5]. In
this series, deaths related to chemotherapy toxicities wereuncommon (3%) despite the high number of chemother-
apy lines administered to patients. The two first lines were
involved in all of these deaths.
The short PFS observed with single-agent regimens
[9-11,23,24] in first line does not necessarily indicate a
failure of the global treatment strategy, if the progres-
sion can be identified before the occurrence of severe
cancer-related symptoms, and if a switch to another
chemotherapy is possible at progression. Therefore, a
treatment strategy, including several lines of chemo-
therapy, should be formally compared with first-line
combinations of multiple drugs in randomized con-
trolled trials. Overall survival and a symptom scale
should be the two major endpoints in such trials [21],
since progression-free survival should systematically fa-
vored the combination arm. With the increased number
of innovative and active agents, strategy trials should
become more and more important. The administration
of successive chemotherapy lines could spare patients
from severe toxic effects, but might not be as efficient
as combination strategy in controlling symptoms for
patients with severe cancer-related symptoms or with rap-
idly progressive disease. The combination of cisplatin-5FU
plus cetuximab might then be preferred in first-line given
its higher response rate. The eligibility criteria for a
treatment strategy with successive chemotherapy lines
were not investigated in this retrospective series, but
only patients without severe cancer-related symptoms,
with low tumor burden and who are eligible for a close
follow-up were treated with this strategy. Given the
increasing number of efficient drugs for the treatment
of recurrent and/or metastatic HNSCC, the design of
future clinical trials in this setting should define the
successive lines to be used after failure of the first line
therapy (when the investigational drug is evaluated in
first line). The primary endpoint might then be the time
to strategy failure, defined as the sum of PFS of the two
or three planned treatment course. In conclusion, our
results are very encouraging, but subsequent efficient
drugs are now strongly needed.
Conclusions
The survival outcomes of patients treated in the first-line
setting with chemotherapy regimens adapted to their
functional status, followed by several subsequent regimens
were comparable with published outcomes of patients
treated by platinum, 5-FU and cetuximab. The administra-
tion of successive chemotherapy lines could spare patients
from severe toxic effects, but might not be as efficient as
combination strategy in controlling symptoms for patients
with severe cancer-related symptoms or with rapidly pro-
gressive disease. It is a reasonable treatment option for pa-
tients with impaired functional status or severe organ
failure to avoid the high toxicity of combination strategy.
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